N-ALKYLCARBONYL-AMINO ACID ESTER AND N-ALKYLCARBONYL-AMINO LACTONE COMPOUNDS AND THEIR USE

• US 20110160303A1
• Filed: 02/18/2011
• Published: 06/30/2011
• Est. Priority Date: 03/29/2005
• Status: Abandoned Application

• Current Assignee: Edward Tak Wei
• Original Assignee: Edward Tak Wei
• Inventors: WEI, Edward Tak
• Application Number:
  US13/030,232
• Publication Number:
  US 20110160303A1
• Time in Patent Office: Days
• US Class Current: 514/529
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/14 Antitussive agents
• CPC Class Codes: C07C 233/63 having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
• CPC Class Codes: C07C 2601/14 The ring being saturated
• CPC Class Codes: C07D 307/33 in position 2, the oxygen atom being in its keto or unsubstituted enol form
• CPC Class Codes: C07D 309/30 Oxygen atoms, e.g. delta-lactones
• CPC Class Codes: C07D 313/04 not condensed with other rings

Abstract

The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid ester and N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts of irritation, itch, and pain in the skin and in the linings of the oral cavity and upper respiratory tract, for example, in methods of treatment of cough and/or asthma.

Claims

1. A compound which is (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid ethyl ester.

2. A composition comprising the compound according to claim 1, and a delivery vehicle for delivering the compound to a human, wherein the delivery vehicle is a pharmaceutically acceptable carrier or diluent.

3. The composition according to claim 2, wherein the delivery vehicle is adapted to deliver the compound to the oral cavity, oropharynx, or the upper respiratory tract of the human.

4. The composition according to claim 2, wherein the compound is present in the composition in an amount of 1 to 10 mg.

5. The composition according to claim 2, wherein the compound is present in the composition in an amount of 0.01 to 2% wt/vol.

6. The composition according to claim 2, wherein the composition further comprises a polyhydric alcohol.

7. The composition according to claim 2, wherein the composition further comprises a mucoadhesive polymer.

8. A method for the treatment of cough in a human, comprising:

contacting the composition according to claim 2 with the oral cavity, oropharynx, or upper airways of said human,

thereby delivering an amount of the compound therapeutically effective for alleviation of cough.

9. A method for the treatment of a sense of irritation in the upper airways of a human, comprising:

contacting the composition according to claim 2 with the oral cavity, oropharynx, or upper airways of said human,

thereby delivering an amount of the compound therapeutically effective for alleviation of the sense of irritation.

10. A method for the treatment of the symptoms of asthma, chronic obstructive pulmonary disease, or other diseases of the upper airways in a human, comprising:

contacting the composition according to claim 2 with the oral cavity, oropharynx, or upper airways of said human,

thereby delivering an amount of the compound therapeutically effective for alleviation of the symptoms of asthma, chronic obstructive pulmonary disease, or other diseases of the upper airways.